600056 中国医药
午间休市 06-17 11:28:52
资讯
新帖
简况
中国医药最新公告：子公司天方药业获阿哌沙班原料药上市批准
证券之星 · 06-08
中国医药最新公告：子公司天方药业获阿哌沙班原料药上市批准
艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌
智通财经网 · 06-04
艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌
股市必读：中国医药（600056）6月2日董秘有最新回复
证券之星 · 06-03
股市必读：中国医药（600056）6月2日董秘有最新回复
中国医药：公司目前经营正常
证券之星 · 06-02
中国医药：公司目前经营正常
每周股票复盘：中国医药（600056）子公司卡络磺钠注射液通过一致性评价
证券之星 · 05-31
每周股票复盘：中国医药（600056）子公司卡络磺钠注射液通过一致性评价
产业瞭望｜不止于“赚钱”：从科创板创新药企一季报透视中国医药创新的质变时刻
经济参考网 · 05-30
产业瞭望｜不止于“赚钱”：从科创板创新药企一季报透视中国医药创新的质变时刻
中国医药(600056.SH)：子公司卡络磺钠注射液通过仿制药质量和疗效一致性评价
智通财经 · 05-29
中国医药(600056.SH)：子公司卡络磺钠注射液通过仿制药质量和疗效一致性评价
股市必读：中国医药（600056）5月21日披露最新机构调研信息
证券之星 · 05-22
股市必读：中国医药（600056）5月21日披露最新机构调研信息
每周股票复盘：中国医药（600056）2025年净利下降18.77%
证券之星 · 05-17
每周股票复盘：中国医药（600056）2025年净利下降18.77%
中国医药（600056）披露2025年年度股东会会议资料，5月13日股价下跌2.06%
证券之星 · 05-13
中国医药（600056）披露2025年年度股东会会议资料，5月13日股价下跌2.06%
每周股票复盘：中国医药（600056）股东户数下降1.83%，一季报净利增5.58%
证券之星 · 05-02
每周股票复盘：中国医药（600056）股东户数下降1.83%，一季报净利增5.58%
中国医药新注册《医药医疗健康业务数据分析软件V1.0》等4个项目的软件著作权
证券之星 · 05-01
中国医药新注册《医药医疗健康业务数据分析软件V1.0》等4个项目的软件著作权
中国医药（600056）2026年一季报简析：净利润同比增长5.58%，盈利能力上升
证券之星 · 04-30
中国医药（600056）2026年一季报简析：净利润同比增长5.58%，盈利能力上升
中国医药（600056）披露2026年第一季度报告全文，4月28日股价上涨0.1%
证券之星 · 04-28
中国医药（600056）披露2026年第一季度报告全文，4月28日股价上涨0.1%
图解中国医药一季报：第一季度单季净利润同比增长5.58%
证券之星 · 04-28
图解中国医药一季报：第一季度单季净利润同比增长5.58%
股市必读：中国医药年报 - 第四季度单季净利润同比下降82.53%
证券之星 · 04-27
股市必读：中国医药年报 - 第四季度单季净利润同比下降82.53%
中国医药(600056)3月31日股东户数12.9万户，较上期减少1.83%
证券之星 · 04-25
中国医药(600056)3月31日股东户数12.9万户，较上期减少1.83%
图解中国医药年报：第四季度单季净利润同比下降82.53%
证券之星 · 04-25
图解中国医药年报：第四季度单季净利润同比下降82.53%
小摩：中国医药板块获利回吐 为良好入场良机
智通财经网 · 04-24
小摩：中国医药板块获利回吐 为良好入场良机
中国医药最新公告：子公司获得注射用尼可地尔药品注册证书
证券之星 · 04-20
中国医药最新公告：子公司获得注射用尼可地尔药品注册证书
加载更多
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是化学制剂、诊断药品及试剂、医用耗材、医疗器械、特医产品、医美产品、中成药、中药饮片、配方颗粒、生物制剂、营养保健品。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":9.03,"timestamp":1781666932000,"preClose":9.08,"halted":0,"volume":4192420,"delay":0,"changeRate":-0.0055,"floatShares":1495000000,"shares":1496000000,"eps":0.327,"marketStatus":"午间休市","change":-0.05,"latestTime":"06-17 11:28:52","open":9.09,"high":9.12,"low":9,"amount":37941600,"amplitude":0.0132,"askPrice":9.03,"askSize":706,"bidPrice":9.02,"bidSize":66,"shortable":0,"etf":0,"ttmEps":0.327,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781672400000},"marketStatusCode":3,"adr":0,"adjPreClose":9.08,"symbolType":"stock","openAndCloseTimeList":[[1781659800000,1781667000000],[1781672400000,1781679600000]],"highLimit":9.99,"lowLimit":8.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.13,"roa":"--","peRate":27.614679,"roe":"1.53%","epsLYR":0.3164,"committee":0.598996,"marketValue":13508000000,"turnoverRate":0.0028,"status":1,"floatMarketCap":13503000000},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2641100904","title":"中国医药最新公告：子公司天方药业获阿哌沙班原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100904","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100904?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:09","pubTimestamp":1780909783,"startTime":"0","endTime":"0","summary":"中国医药(600056.SH)公告称，公司下属全资子公司天方药业收到国家药监局核准签发的阿哌沙班《化学原料药上市申请批准通知书》。该药品主要用于预防髋关节或膝关节置换术后静脉血栓栓塞事件。截至公告日，天方药业在该药品累计投入约1224万元。此次获批将进一步拓展公司产品领域，但未来销售可能受市场环境等不确定因素影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","BK0250","BK0082","BK0185","BK0188","BK0010","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159152","title":"艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159152","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640159152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:53","pubTimestamp":1780574025,"startTime":"0","endTime":"0","summary":"本次权益变动完成后，国药集团(北京)科技创新研究院有限公司将成为公司控股股东，公司实际控制人将变更为中国医药集团有限公司。公司股票于2026年6月5日开市起复牌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾德生物(300685.SZ)：实控人将变更为中国医药集团有限公司 明起复牌","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2460026573.USD","BK0250","600056","BK0175","BK0082","BK0185","BK0188","BK0239","300685","BK0042","IE0005HP3H50.USD","BK0028","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640947225","title":"股市必读：中国医药（600056）6月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640947225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640947225?lang=zh_cn&edition=full","pubTime":"2026-06-03 01:45","pubTimestamp":1780422315,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，中国医药报收于9.87元，下跌0.8%，换手率0.79%，成交量11.75万手，成交额1.17亿元。董秘最新回复投资者： 请问公司，公司董秘在4月2日回答关于公司创新药的问答。公司重视投资者沟通交流，珍视投资者的宝贵意见，通过多种合规渠道与市场保持良好互动及有效沟通。股价波动受宏观经济、市场情绪、行业周期等多重因素影响，敬请注意投资风险。当日关注点来自交易信息汇总：6月2日主力资金净流出1419.71万元，占总成交额12.16%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300001928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","600056","BK0185","BK0010","BK0028","BK0082","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640391669","title":"中国医药：公司目前经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2640391669","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640391669?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:51","pubTimestamp":1780390289,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药06月02日在投资者关系平台上答复投资者关心的问题。公司目前经营正常，积极推进战略转型和动能转换，持续探索新型业务模式，加快构建新发展格局。公司始终坚持将股东利益放在重要位置，连续三年制定“提质增效重回报”行动方案，围绕提高经营质效、治理质效、信披质效和回报投资者质效等多方面开展工作，推动公司高质量发展，以更好的回报股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200031588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0250","BK0028","BK0010","BK0082","BK0185","600056","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604167","title":"每周股票复盘：中国医药（600056）子公司卡络磺钠注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604167","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604167?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:36","pubTimestamp":1780169773,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，中国医药报收于9.9元，较上周的9.84元上涨0.61%。本周，中国医药5月27日盘中最高价报9.99元。公司公告汇总中国医药全资子公司海南通用康力制药有限公司收到国家药监局核准签发的三份卡络磺钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。卡络磺钠注射液适用于泌尿系统、上消化道、呼吸道和妇产科出血疾病，以及手术出血的预防与治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600056","BK0082","BK0175","BK0028","BK0185","BK0010","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639605795","title":"产业瞭望｜不止于“赚钱”：从科创板创新药企一季报透视中国医药创新的质变时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2639605795","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639605795?lang=zh_cn&edition=full","pubTime":"2026-05-30 13:43","pubTimestamp":1780119785,"startTime":"0","endTime":"0","summary":"2026年一季度，科创板28家创新药公司交出亮眼“成绩单”：合计实现营业收入约192.33亿元，净利润19.94亿元，行业整体实现盈利，营收在2025年高基数基础上续增超30%。其中，龙头企业百济神州表现尤为突出，2025年首次实现全年盈利后，2026年一季度利润已超去年全年，彰显国产创新药企与国际龙头比肩的综合实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605303755050735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600056","159982","BK0010","BK0028","BK1161","06978","BK0188","BK1574","BK0082","BK0185","BK0250","BK0175","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639640589","title":"中国医药(600056.SH)：子公司卡络磺钠注射液通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2639640589","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639640589?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:04","pubTimestamp":1780041859,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司海南通用康力制药有限公司收到国家药品监督管理局核准签发的三份卡络磺钠注射液(规格分别为5ml:25mg、10ml:50mg、20ml:100mg)《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。据悉，卡络磺钠注射液用于泌尿系统、上消化道、呼吸道和妇产科出血疾病。对泌尿系统疗效较显著，亦可用于手术出血的预防及治疗等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国医药(600056.SH)：子公司卡络磺钠注射液通过仿制药质量和疗效一致性评价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0010","BK0250","BK0082","BK0188","600056","BK0028","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637565353","title":"股市必读：中国医药（600056）5月21日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2637565353","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637565353?lang=zh_cn&edition=full","pubTime":"2026-05-22 02:12","pubTimestamp":1779387131,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，中国医药报收于9.9元，下跌0.5%，换手率0.8%，成交量11.96万手，成交额1.19亿元。来自公司公告汇总：中国医药于2026年5月20日召开2025年年度股东会，审议通过包括年度报告、利润分配方案等13项议案，表决结果合法有效。公司回应称，截至2026年3月31日，股东总数为129,001。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200002816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600056","BK0028","BK0175","BK0188","BK0082","BK0185","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636766061","title":"每周股票复盘：中国医药（600056）2025年净利下降18.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636766061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636766061?lang=zh_cn&edition=full","pubTime":"2026-05-17 02:35","pubTimestamp":1778956511,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，中国医药报收于10.07元，较上周的10.33元下跌2.52%。本周，中国医药5月12日盘中最高价报10.68元。本周关注点公司公告汇总：中国医药2025年归母净利润4.73亿元，同比下降18.77%公司公告汇总：公司拟每10股派息0.9491元（含税），末期分红待批公司公告汇总：2025年营收353.62亿元，同比增长0.33%公司公告汇总中国医药健康产业股份有限公司召开2025年年度股东会，审议公司2025年年度报告、董事会工作报告、财务决算报告、利润分配方案等议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0185","BK0188","BK0028","600056","BK0175","BK0250","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635788857","title":"中国医药（600056）披露2025年年度股东会会议资料，5月13日股价下跌2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635788857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635788857?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:01","pubTimestamp":1778666473,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，中国医药报收于10.44元，较前一交易日下跌2.06%，最新总市值为156.17亿元。中国医药健康产业股份有限公司于近日披露《2025年年度股东会会议资料》。公告显示，公司拟召开2025年年度股东会，审议公司2025年年度报告、董事会工作报告、财务决算报告、利润分配方案等议案。2025年公司实现营业收入353.62亿元，同比增长0.33%；归属于上市公司股东的净利润4.73亿元，同比下降18.77%；扣除非经常性损益后净利润3.76亿元，同比增长16.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0175","BK0188","BK0082","BK0010","BK0250","BK0028","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623300","title":"每周股票复盘：中国医药（600056）股东户数下降1.83%，一季报净利增5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623300?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:57","pubTimestamp":1777672631,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，中国医药报收于10.36元，较上周的10.43元下跌0.67%。本周，中国医药4月27日盘中最高价报10.42元。关于召开2025年年度暨2026年第一季度业绩说明会的公告中国医药将于2026年5月21日15:00-16:00通过上证路演中心以视频和网络互动方式召开2025年年度暨2026年第一季度业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","BK0188","BK0185","600056","BK0010","BK0082","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632650371","title":"中国医药新注册《医药医疗健康业务数据分析软件V1.0》等4个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2632650371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632650371?lang=zh_cn&edition=full","pubTime":"2026-05-01 01:56","pubTimestamp":1777571773,"startTime":"0","endTime":"0","summary":"证券之星消息，近日中国医药新注册了4个项目的软件著作权，包括《医药医疗健康业务数据分析软件V1.0》、《审计追责报告汇总软件V1.0》、《销售预测分析系统V1.0》、《投资报告管理系统V1.0》等。今年以来中国医药新注册软件著作权10个。通过天眼查大数据分析，中国医药健康产业股份有限公司共对外投资了29家企业，参与招投标项目817次；财产线索方面有商标信息5条，专利信息4条，著作权信息6条；此外企业还拥有行政许可16个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100000610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0028","BK0175","BK0250","BK0082","159180","09939","BK0185","BK0188","BK1515","BK0010","159760","BK1574","159938","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631527675","title":"中国医药（600056）2026年一季报简析：净利润同比增长5.58%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631527675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631527675?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:02","pubTimestamp":1777500178,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期中国医药发布2026年一季报。截至本报告期末，公司营业总收入81.89亿元，同比下降3.97%，归母净利润1.82亿元，同比上升5.58%。本报告期中国医药盈利能力上升，毛利率同比增幅0.14%，净利率同比增幅5.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000018405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630585536","title":"中国医药（600056）披露2026年第一季度报告全文，4月28日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630585536","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630585536?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:24","pubTimestamp":1777386250,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，中国医药报收于10.28元，较前一交易日上涨0.1%，最新总市值为153.78亿元。该股当日开盘10.21元，最高10.38元，最低10.2元，成交额达1.26亿元，换手率为0.82%。近日，中国医药发布《2026年第一季度报告全文》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800065270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0175","600056","BK0010","BK0028","BK0082","BK0250","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306106","title":"图解中国医药一季报：第一季度单季净利润同比增长5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306106","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630306106?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:29","pubTimestamp":1777375797,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药2026年一季报显示，一季度公司主营收入81.89亿元，同比下降3.97%；归母净利润1.82亿元，同比上升5.58%；扣非净利润1.77亿元，同比上升9.97%；负债率61.04%，投资收益761.53万元，财务费用2944.25万元，毛利率10.61%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800055456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337394","title":"股市必读：中国医药年报 - 第四季度单季净利润同比下降82.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337394","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630337394?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:21","pubTimestamp":1777249276,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日中国医药披露，截至2026年3月31日公司股东户数为12.9万户，较12月31日减少2401.0户，减幅为1.83%。公司公告汇总2025年年度报告摘要中国医药健康产业股份有限公司2025年年度报告摘要显示，公司2025年实现营业收入35,361,621,734.95元，同比增长0.34%；归属于上市公司股东的净利润为473,229,055.14元，同比下降18.77%；扣除非经常性损益后的净利润为376,478,717.77元，同比增长16.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700007574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630708668","title":"中国医药(600056)3月31日股东户数12.9万户，较上期减少1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630708668","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630708668?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:02","pubTimestamp":1777107763,"startTime":"0","endTime":"0","summary":"证券之星消息，近日中国医药披露，截至2026年3月31日公司股东户数为12.9万户，较12月31日减少2401.0户，减幅为1.83%。在医药商业行业个股中，中国医药股东户数高于行业平均水平，截至3月31日，医药商业行业平均股东户数为4.58万户。从股价来看，2025年12月31日至2026年3月31日，中国医药区间跌幅为0.58%，在此期间股东户数减少2401.0户，减幅为1.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500031848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0188","BK0028","BK0185","BK0082","BK0175","BK0010","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630294598","title":"图解中国医药年报：第四季度单季净利润同比下降82.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630294598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630294598?lang=zh_cn&edition=full","pubTime":"2026-04-25 01:15","pubTimestamp":1777050919,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药2025年年报显示，当年度公司主营收入353.62亿元，同比上升0.34%；归母净利润4.73亿元，同比下降18.77%；扣非净利润3.76亿元，同比上升16.49%；其中2025年第四季度，公司单季度主营收入94.67亿元，同比上升12.26%；单季度归母净利润1846.51万元，同比下降82.53%；单季度扣非净利润-1793.72万元，同比上升79.01%；负债率61.04%，投资收益-6801.02万元，财务费用1.1亿元，毛利率10.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500003740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629811562","title":"小摩：中国医药板块获利回吐 为良好入场良机","url":"https://stock-news.laohu8.com/highlight/detail?id=2629811562","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629811562?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:52","pubTimestamp":1777020733,"startTime":"0","endTime":"0","summary":"该行认为昨日生科股医药股回调，是建立中国医疗保健配置以迎接下一波催化剂驱动上涨行情的良好进场时机。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260424/20260424164629_20525.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260424/20260424164629_20525.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1244550494.USD","IE00BDCRKT87.USD","LU2242649171.HKD","JPMO","IE00BLSP4239.USD","BK0010","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1974910355.USD","LU1988902786.USD","LU2456880835.USD","LU1670627923.USD","JPO","LU0170899867.USD","BK4504","600056","LU2236285917.USD","LU2023250330.USD","LU0689472784.USD","LU2552382058.USD","LU0203345920.USD","LU0238689110.USD","BK4516","LU1162221912.USD","LU2505996681.GBP","LU2237443978.SGD","LU1267930490.SGD","LU0211328371.USD","LU0323591593.USD","LU0320765646.SGD","LU1116320901.HKD","LU0251132253.USD","LU2054465674.USD","LU0211326755.USD","LU2237443465.HKD","BK4533","LU2552382132.HKD","LU1244550577.SGD","LU0006306889.USD","LU1366192091.USD","LU0106831901.USD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU0496365809.HKD","LU2430703095.HKD","LU0211326839.USD","LU0106261372.USD","LU0208291251.USD","LU0070302665.USD","LU1280957306.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745479","title":"中国医药最新公告：子公司获得注射用尼可地尔药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745479","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745479?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:13","pubTimestamp":1776676396,"startTime":"0","endTime":"0","summary":"中国医药公告称，公司下属全资子公司天方药业近日收到国家药监局核准签发的两份注射用尼可地尔《药品注册证书》。该药品主要用于治疗急性心力衰竭和不稳定型心绞痛，国内已有42家生产企业获得批件。截至公告披露日，该药品累计投入约808万元。数据显示，2024年中国三大终端六大市场该药品销售额约为6.21亿元，2025年前三季度约为2.18亿元。本次获证将进一步夯实公司原料制剂一体化发展战略，有利于丰富公司产品线矩阵，完善产品布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0185","BK0188","BK0028","600056","BK0175","BK0250","BK0082"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781669687579,"stockEarnings":[{"period":"1week","weight":-0.0141},{"period":"1month","weight":-0.0983},{"period":"3month","weight":-0.1344},{"period":"6month","weight":-0.1482},{"period":"1year","weight":-0.1157},{"period":"ytd","weight":-0.121}],"compareEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":-0.0105},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0556},{"period":"1year","weight":0.2075},{"period":"ytd","weight":0.031}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"129001人(较上一季度减少1.83%)","perCapita":"11591股","listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","registeredCapital":"149587万元","survey":" 中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是化学制剂、诊断药品及试剂、医用耗材、医疗器械、特医产品、医美产品、中成药、中药饮片、配方颗粒、生物制剂、营养保健品。","listedPrice":7.02},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}